聚乙二醇干扰素
医学
免疫学
病毒学
慢性肝炎
病毒
利巴韦林
作者
Man‐Fung Yuen,Young‐Suk Lim,Ki Tae Yoon,Tien-Huey Lim,Jeong Heo,Pisit Tangkijvanich,Won Young Tak,Vaidehi Thanawala,D. C. Cloutier,Shenghua Mao,Andre Arizpe,Andrea L. Cathcart,Sneha Gupta,Carey Hwang,Edward Gane
标识
DOI：10.1016/s2468-1253(24)00237-1
摘要
Chronic hepatitis B virus (HBV) remains a global concern, with current treatments achieving low rates of HBsAg seroclearance. VIR-2218 (elebsiran), a small interfering RNA agent against HBV transcripts, reduces HBsAg concentrations. We aimed to evaluate the safety and antiviral activity of VIR-2218 with and without pegylated interferon-alpha-2a treatment in participants with chronic HBV.
科研通智能强力驱动
Strongly Powered by AbleSci AI
cdercder
eee
bc
SYLH
不倦
冰魂
昏睡的蟠桃
科研助手6
遇上就这样吧
pluto
YifanWang
余味
HeWang
科研小民工
归尘
dodo
路人
小墨
iNk
aprilvanilla
皖公网安备34019202002308
